Drug Pipeline

Benmelstobart Clinical Trials

Data updated daily from ClinicalTrials.gov — last refresh 2026-06-12
6
Active Studies
1
Recruiting
1
Phase 3
5
Top Sponsors
What Changed in the Last 30 Days
First PostedNew Trial FilingPhaseStatus
2026-06-11 NCT07643350 Efficacy and Safety of Induction Benmelstobart Plus Anlotinib and Chemotherapy Followed… Phase 2 Not Yet Recruiting
Active Studies by Phase
Phase 3
1
Phase 2
5
Active Trials
NCT IDTitleConditionStatus
Phase 3
NCT07385079 Anlotinib Plus Immunotherapy and Chemoradiotherapy for High-Risk Nasopharyngeal Carcinoma Nasopharyngeal Cancinoma (NPC) Not Yet Recruiting
Phase 2
NCT05582499 Fudan University Shanghai Cancer Center Breast Cancer Precision Platform Series Study… Breast Neoplasm Recruiting
NCT07537777 Benmelstobart Plus Anlotinib Combined With SBRT for Patients With Hepatocellular… Hepatocellular Carcinoma (HCC) Not Yet Recruiting
NCT07538258 Benmelstobart Plus Anlotinib, Chemotherapy and Thoracic Radiation for Limited-Stage Small… Limited-stage Small Cell Lung Cancer (LS-SCLC) Not Yet Recruiting
NCT07538271 A Study of Benmelstobart, Anlotinib, Chemotherapy and Thoracic Radiotherapy for People… SCLC, Extensive Stage Not Yet Recruiting
NCT07643350 Efficacy and Safety of Induction Benmelstobart Plus Anlotinib and Chemotherapy Followed… NSCLC Not Yet Recruiting
Sponsors Running Benmelstobart Trials
Yayi He (2) Fudan University (1) Sun Yat-sen University (1) Nanfang Hospital, Southern Medical University (1) The Third Xiangya Hospital of Central South University (1)
Disease Areas
Small Cell Lung Cancer (2) Breast Cancer (1) Triple-Negative Breast Cancer (1) HER2-Positive Breast Cancer (1) Liver Cancer (1) Lung Cancer (1) Non-Small Cell Lung Cancer (NSCLC) (1)
Get alerts when Benmelstobart trials change
Status changes, date slips, and new filings — detected daily, delivered to your inbox.
Start monitoring free